Source: Annual Congress 2012 - New biomarkers for lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. Schultz, S. Marwitz, B. Baron-Luehr, G. Zissel, C. Kugler, K. Rabe, P. Zabel, E. Vollmer, J. Gerdes, T. Goldmann (Borstel, Germany). MAdL: A new diagnostic marker for adenocarcinomas. Eur Respir J 2012; 40: Suppl. 56, 4219

Member's Comments

No comment yet.

Related content which might interest you: The value of immunohistochemical markers in the differential diagnosis of adenocarcinomas Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Hyaluronan: A novel sputum marker for the screening and diagnosis of lung cancer patients Source: Annual Congress 2012 - Early detection of lung cancer Year: 2012 The clinical effect and expression of alpha-methylacyl-CoA racemace (AMACR) in the differential diagnosis of malign mesothelioma and adenocarcinoma of lung Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 D2-40 as a diagnostic marker for pulmonary squamous cell carcinoma Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 The smellprint of mesothelioma cells: intrinsic biomarkers for diagnosis and subtyping Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens Source: Eur Respir Rev, 26 (144) 170007; 10.1183/16000617.0007-2017 Year: 2017 Contribution of immunohistochemical (IHC) markers to the diagnosis of pulmonary carcinoids Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Identification of genes with diagnostic and prognostic value in lung cancer. Source: International Congress 2019 – Biology of lung cancer Year: 2019 Serum napsin A is a novel diagnostic and monitoring marker for interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis Source: Eur Respir J 2008; 31: 854-859 Year: 2008 The diagnostic value of mucinous carcinoma - associated antigen (MCA) testin differentiation of malignant from benign pleural effusion (PE) Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Validation of diagnostic molecular markers in bronchial fluid for lung cancer Source: Annual Congress 2011 - Progress in endoscopy for the diagnosis of lung cancer Year: 2011 Early detection of lung cancer: role of biomarkers Source: Eur Respir J 2003; 21: 36S-44S Year: 2003 Detection of k-ras mutations in cytologic specimen of lung cancer patients as predictive factor of targeted therapy Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Pathology of lung cancer: histology, cytology, immunohistochemistry and molecular pathology Source: Eur Respir Mon; 2010: 48: 272–296 Year: 2010 The clinical value of autofluorescence bronchoscopy for the diagnosis of lung cancer Source: Eur Respir J 2006; 28: 915-919 Year: 2006 Pro-GRP as a diagnostic tool in SCLC in comparison to NSE Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002